National Center For Advancing Translational Sciences; Notice of Closed Meeting, 61919 [2019-24677]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 220 / Thursday, November 14, 2019 / Notices
•
•
•
khammond on DSKJM1Z7X2PROD with NOTICES
•
•
—The protein band Raf from mouse
lung endothelial cells (MLECs) at
the time points 0, 5, 10, 20, and 30
minutes in Figure 5A (bottom
panel, lanes 1–5) of JCI 2005
—the protein band FAK(P) from
MRECs at the time points 20 and 40
minutes in Figure 7A (top panel,
lanes 2 and 4) of IOVS 2009 and
Figure 5A (top panel, lanes 2 and 4)
of grant application R01 EY020539–
01
—the protein band FAK from MRECs
at the time points 0, 20, 20, 40, and
40 minutes in Figure 7A (bottom
panel, lanes 1–5) of IOVS 2009 and
Figure 5A (bottom panel, lanes 1–5)
of grant application R01 EY020539–
01
falsifying images of corneas by
reusing and falsely labeling one image
as two different experiments:
—CNV cornea treated with arresten
(a1(IV)NC1) in Figure 13 (right
panel) of grant application R01
EY020539–01
—CNV cornea treated with tumstatin
(a3(IV)NC1) in Figure 3A (right
panel) of JCEO Sub 2011
falsifying images of corneal sections
by reusing and falsely labeling one
image as two different experiments:
—CNV cornea treated with arresten
(a1(IV)NC1) in Figure 14 (right
panel) of grant application R01
EY020539–01
—CNV cornea treated with tumstatin
(a3(IV)NC1) in Figure 4 (right
panel) of JCEO Sub 2011
falsifying endothelial cell migration
assays by reusing and falsely labeling
one image as two different
experiments:
—MRECs treated with vascular
endothelial growth factor (VEGF)
and arresten (a1(IV)NC1) in Figure
2A (top right panel) of IOVS 2009
and Figure 2 (top right panel) of
grant application R01 EY020539–01
—HUVECs treated with only VEGF in
Figure 1C (middle panel) of grant
application R21 CA155796–01 and
Figure 2C (second panel) of grant
application R01 CA166195–01
falsifying endothelial cell migration
assays by reusing and falsely labeling
one image as two different
experiments:
—MRECs treated with VEGF in Figure
2A (top middle panel) of IOVS 2009
and Figure 2 (top middle panel) of
grant application R01 EY020539–01
—MRECs treated with basic fibroblast
growth factor (bFGF) in Figure 3A
(second panel) of CER 2010
falsifying endothelial cell migration
assays by reusing and falsely labeling
VerDate Sep<11>2014
17:47 Nov 13, 2019
Jkt 250001
one image as two different
experiments:
—MRECs treated with bFGF and
arresten (a1NC1) in Figure 3A
(fourth panel) of CER 2010
—MRECs treated with VEGF and
arresten (a1NC1) in Figure 2A
(bottom middle panel) of IOVS 2009
and Figure 2 (bottom middle panel)
of grant application R01 EY020539–
01
• falsifying endothelial cell migration
assays by reusing and falsely labeling
one image as three different
experiments:
—MRECs treated with bFGF and 10
mg/ml arresten (a1NC1) in Figure
3A (fifth panel) of CER 2010
—HUVECs treated with VEGF and 0.5
mM hexastatin (a6NC1) in Figure 1C
(last panel) of grant application R21
CA155796–01
—HUVECs treated with VEGF and
0.25 mM hexastatin (a6NC1) in
Figure 2C (third panel) of grant
application R01 CA166195–01
The following administrative actions
have been implemented, beginning on
August 24, 2019:
(1) Respondent is debarred for a
period of five (5) years from eligibility
for any contracting or subcontracting
with any agency of the United States
Government and from eligibility for, or
involvement in, nonprocurement
programs of the United States
Government referred to as ‘‘covered
transactions’’ pursuant to HHS’
Implementation (2 CFR part 376 et seq.)
of Office of Management and Budget
(OMB) Guidelines to Agencies on
Governmentwide Debarment and
Suspension, 2 CFR part 180 (collectively
the ‘‘Debarment Regulations’’);
(2) Respondent is prohibited from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant for a period of five (5) years;
and
(3) in accordance with 42 CFR 93
§§ 93.407(a)(1) and 93.411(b), HHS will
send a notice of the findings and of the
need for correction or retraction to the
pertinent journals for each of the
following:
• Biochemistry 2000;39(42):12929–
12938
• Proc. Natl. Acad. Sci. U.S.A.
2003;100(8):4766–4771
• The Journal of Clinical Investigation
2005;115(10):2801–2810
• Invest. Ophthalmol. Vis. Sci.
2009;50(10):4567–4575
• Pharmaceutical Research
2008;25(12):2731–2739
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
61919
• Scientific Reports 2014;4(4136):1–9
• Current Eye Res. 2010 Jan;35(1):44–55
Elisabeth A. Handley,
Interim Director, Office of Research Integrity.
[FR Doc. 2019–24689 Filed 11–13–19; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center For Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; CTSA.
Date: January 24, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Victor Henriquez, Ph.D.,
Scientific Review Officer, Office of Scientific
Director, National Center for Advancing
Translational Sciences (NCATS), National
Institutes of Health, 6701 Democracy Blvd.,
Democracy 1, Room 1080, Bethesda, MD
20892–4878, 301–435–0813, henriquv@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: November 7, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–24677 Filed 11–13–19; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\14NON1.SGM
14NON1
]]>Agencies
[Federal Register Volume 84, Number 220 (Thursday, November 14, 2019)]
[Notices]
[Page 61919]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-24677]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center For Advancing Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel; CTSA.
Date: January 24, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda North Marriott Hotel & Conference Center, 5701
Marinelli Road, Bethesda, MD 20852.
Contact Person: Victor Henriquez, Ph.D., Scientific Review
Officer, Office of Scientific Director, National Center for
Advancing Translational Sciences (NCATS), National Institutes of
Health, 6701 Democracy Blvd., Democracy 1, Room 1080, Bethesda, MD
20892-4878, 301-435-0813, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.859,
Pharmacology, Physiology, and Biological Chemistry Research; 93.350,
B--Cooperative Agreements; 93.859, Biomedical Research and Research
Training, National Institutes of Health, HHS)
Dated: November 7, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-24677 Filed 11-13-19; 8:45 am]
BILLING CODE 4140-01-P
